Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Retains Simvastatin Share As New Entrants Struggle To Meet Demand

Executive Summary

Generic companies may find it difficult to assess how much supply to produce when a large product loses 180-day exclusivity, comments by Teva Pharmaceuticals USA CEO William Marth suggest

You may also be interested in...



Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver

The success of generic companies will be determined more by the breadth and quality of their offerings than product pricing, Lehman Brothers Senior VP-Specialty Pharmaceutical Research Rich Silver told the Generic Pharmaceutical Association

Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver

The success of generic companies will be determined more by the breadth and quality of their offerings than product pricing, Lehman Brothers Senior VP-Specialty Pharmaceutical Research Rich Silver told the Generic Pharmaceutical Association

Financial Analysts Roundtable Part II: Changes On Capitol Hill, FDA’s Risk Threshold And The Future Of The Cholesterol Market

The following excerpts are from a conversation "The Pink Sheet" had with three large cap pharmaceutical analysts, Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin, concerning the outlook for the drug industry in 2007. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. The 4first part of the series, which covered Medicare Part D, big pharma diversification, and the outlook for M&A, appeared in the Feb. 5 issue of "The Pink Sheet."

UsernamePublicRestriction

Register

PS048087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel